PI anaemia was observed in 61% and 33% required BT during the first 12 weeks of treatment. ITPase deficiency was associated with less PI anaemia (40.7% vs 68.2%, p = 0.001). No association between week 4 Hb decline and gender, age <45 yrs, fibrosis stage, treatment history or IL28B genotype was observed. The proportion of patients requiring BT was lower in those with ITPase deficiency (7.4% vs 21%). A multivariable model including ITPase activity, gender, age, fibrosis stage, and RBV dose (mg/kg) was used to determine factors associated with BT requirement. Both gender and ITPase activity were independent predictors of requiring a BT (male

gender OR 0.2, p = 0.003; wild-type ITPase activity OR 3.3, p = 0.04). Conclusions: Baseline ITPA genotype predicts the development of early and significant anaemia during PI therapy for HCV and identifies patients who are at higher Alvelestat datasheet risk for requiring a blood transfusion during therapy. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in NVP-AUY922 patients treated for chronic hepatitis C. Nature 2010; 464:405–408. JA HOLMES,1,2 S BONANZINGA,3 MK SANDHU,1 YH KIA,1 M CONGIU,2 SJ BELL,1 T NGUYEN,1 DM ISER,1 KL MELLOR,1 K VISVANATHAN,2,5 W SIEVERT,5,6 DS BOWDEN,3 PV DESMOND,1,2 AJ THOMPSON1,2,3 1Department of Gastroenterology;

St Vincent’s Hospital; Fitzroy; Australia, 2Department of Medicine, University of Melbourne; St Vincent’s Hospital; Fitzroy; Australia, 3Victorian Infectious Diseases Reference Laboratory; North Melbourne; selleckchem Australia, 4Department of Medical Imaging; St Vincent’s Hospital; Fitzroy; Australia, 5Infectious Diseases Department; Monash Medical Centre; Monash University; Clayton; Australia, 6Department of Gastroenterology; Monash Medical Centre; Monash University; Clayton; Australia, 7Department of Gastroenterology; Duke University Medical Centre; Duke Clinical Research Institute; Durham; USA Background: In 2009, IL28B genotype (gt) was identified as the strongest baseline predictor of peg-interferon and ribavirin (PR) response for HCV-1. In 2013, a novel dinucleotide

variant in interferon-lambda-4 (IFNL4, ss469415590, ΔG/TT), in high linkage disequilibrium (LD) with IL28B polymorphism, was proposed to be the causal variant. IFNL4 gt was reported to be a better predictor of sustained virological response (SVR). We have performed the first independent validation study of the association between IFNL4 variation, IL28B variation, and PR treatment outcomes in a large cohort of Australian HCV-1/3 patients. Methods: HCV-1/3 patients who received PR were included. IL28B (rs12979860) and IFNL4 (ss469415590) gts were determined from serum (TaqMan allelic discrimination kit, custom designed primers where testing unsuccessful). IFNL4 gt was correlated with rapid virological response (RVR) and SVR, and compared to IL28B gt using logistic regression modeling and LD calculation.